Last edition
News about "T cell engager "
Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval
Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.
T-cell Engager | 26/08/2026 | By News Bureau
AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma
AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
T-cell Engager | 01/07/2026 | By News Bureau | 102
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
T Cell Engager | 20/12/2025 | By News Bureau | 196
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
T Cell Engager | 20/12/2025 | By News Bureau | 196
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy